Evaluation of novel lab-in-a-capsule technology for SIBO diagnosis

Ingestible capsule that analyzes intestinal fluid in real time is as accurate, faster, and less invasive compared to the current clinical standard.

Small intestinal bacterial overgrowth (SIBO) is a gastrointestinal disease that has clinical overlap with irritable bowel syndrome. Current diagnostic methods are invasive or inaccurate, which often leads to empiric use of antibiotics without a clear diagnosis.

Progenity is developing a novel ingestible diagnostic capsule to address this unmet medical need. It has a built-in assay designed to analyze intestinal fluid samples and transmit data in real time. We sought to determine the accuracy of the capsule’s assay in patients with suspected SIBO.

What did we find?

  • A benchtop version of the assay showed 94% agreement with the current diagnostic standard of endoscopic aspiration and total bacterial count.
  • The ingestible capsule provides results within 24 hours, while endoscopy and total bacterial count may take up to 7 days.
  • This lab-in-a-capsule technology represents a promising alternative for SIBO diagnosis.

Presentation

This research was presented at the 2020 American College of Gastroenterology (ACG) annual meeting.

Watch the presentation.

Support